Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces the development of novel pan-KRAS inhibitors of new chemotypes through structure-based drug design, scaffold hopping combined with intense molecular modeling, empowered by the generative chemistry methods of Chemistry42, Insilico’s proprietary generative chemistry platform. Developed in the joint efforts of artificial intelligence and human expertise, the candidate compounds demonstrated pan-KRAS inhibition with potency in the upper nanomolar range. The results have been recently published on ACS Medicinal Chemistry Letters.

Director of ELLIS Institute Finland, prof. Samuel Kaski, receives ERC Advanced Grant of 2.5 M€ to develop new machine learning that is robust, generalizable and engages human experts.

Diego Di Bernardo of the Telethon Institute of Genetics and Medicine (TIGEM) has received a €2.5 million ERC Advanced Grant for DIMERCIRCUITS, a project that combines synthetic biology, artificial intelligence, and systems biology to create programmable genetic circuits. These tools aim to precisely and reversibly control gene expression, paving the way for safer, more personalized gene therapies. Using rare diseases like Friedreich’s ataxia as testbeds, the project could unlock new treatment strategies for a broad range of genetic conditions..